NOKOMIS, Fla. (BUSINESS WIRE) — Biotech innovator Rainbow Coral Corp. and its joint venture partner Nano3D Biosciences (n3D) are combining on the worldwide marketing and distribution of a new technology that makes testing a drug’s potency and toxicity faster and easier.
Nano3D is the developer of a new automated toxicity assay that harnesses the multi-function computing power of the Apple iPod to test a drug’s effects by capturing and charting cell migration data. The Experiment Assistant app, when used with n3D’s n3Dock Station and 3D cell culturing technology, organizes and takes time-lapse images of 3D cell culture growth and migration in the presence of a drug.
Through automation, the BiO Assay system can produce drug toxicity results with minimal effort from researchers in 24 hours, in contrast to the 10 days such tests require using current methods.
“The Experiment Assistant app is going to absolutely slash the time necessary to conduct drug testing, which means pharmaceutical companies will soon be able to get their cutting-edge products to the millions who need them faster,” said RBCC CEO Patrick Brown. “We’re currently consulting with n3D on a worldwide marketing and distribution plan that could make this technology the new standard in testing labs all over the globe.”
RBCC formed a biotech subsidiary, Rainbow BioSciences, to market and develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co., Biogen Idec Inc., Abbott Laboratories and Amgen Inc. Rainbow BioSciences acquired an equity interest in n3D earlier last year.